Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Products & Services

TITLE:

EMA: Meeting highlights from last PRAC meeting

BRIEF:

During the latest meeting of the Pharmacovigilance Risk Assessment Committee (PRAC), several topics were reviewed and one recommendation was adopted, namely Zydelig (idelalisib).

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company